Collecting CAR parts
How Cell Medica plans to use Delenex, Baylor tech in CAR platform for solid tumors
While CAR T cell therapies have produced impressive response rates in blood cancers, the approach has so far shown limited effect in solid tumors, partly due to poor localization of T cells in tumor sites. Cell Medica Ltd. has therefore been assembling a tool kit to develop and improve upon a chimeric antigen receptor natural killer T cell platform.
Unlike T cells, which circulate in the blood, NKT cells localize in solid tumors in response to chemokines produced by tumor cells.
The first step was a June deal with Baylor College of Medicine to co-develop CAR NKT cell therapies to treat cancer.
The second step was